Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.98 EUR | 0.00% | +3.91% | +70.51% |
Apr. 05 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
Mar. 28 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 170 | 69.7 | 39.57 | 68.97 | - | - |
Enterprise Value (EV) 1 | 140.2 | 33.35 | 39.57 | 57.71 | 56.97 | 50.67 |
P/E ratio | -227 x | 25.9 x | -3.57 x | 69 x | 19.1 x | 10 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 3.32 x | 1.25 x | 1.07 x | 1.35 x | 1.17 x | 0.98 x |
EV / Revenue | 2.74 x | 0.6 x | 1.07 x | 1.13 x | 0.97 x | 0.72 x |
EV / EBITDA | 28.8 x | 5.99 x | -2.98 x | 16.8 x | 7.3 x | 3.77 x |
EV / FCF | 79 x | 4.31 x | - | -6.58 x | 74.3 x | 8.04 x |
FCF Yield | 1.27% | 23.2% | - | -15.2% | 1.35% | 12.4% |
Price to Book | 4.18 x | 1.64 x | - | 2.24 x | 2.02 x | 1.69 x |
Nbr of stocks (in thousands) | 8,500 | 8,500 | 8,330 | 8,330 | - | - |
Reference price 2 | 20.00 | 8.200 | 4.750 | 8.280 | 8.280 | 8.280 |
Announcement Date | 3/30/22 | 3/30/23 | 3/28/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | 39.24 | 51.18 | 55.73 | 36.96 | 51.07 | 58.83 | 70.13 |
EBITDA 1 | - | 4.862 | 5.569 | -13.28 | 3.433 | 7.8 | 13.43 |
EBIT 1 | - | 3.116 | 3.876 | -15.16 | 1.433 | 5.067 | 9.567 |
Operating Margin | - | 6.09% | 6.96% | -41.02% | 2.81% | 8.61% | 13.64% |
Earnings before Tax (EBT) 1 | - | 0.2483 | 3.828 | -14.85 | 1.433 | 5.067 | 9.6 |
Net income 1 | -1.183 | -0.7452 | 2.689 | -11.3 | 1.033 | 3.7 | 7.033 |
Net margin | -3.01% | -1.46% | 4.82% | -30.58% | 2.02% | 6.29% | 10.03% |
EPS 2 | - | -0.0880 | 0.3163 | -1.330 | 0.1200 | 0.4333 | 0.8267 |
Free Cash Flow 1 | - | 1.773 | 7.742 | - | -8.767 | 0.7667 | 6.3 |
FCF margin | - | 3.46% | 13.89% | - | -17.17% | 1.3% | 8.98% |
FCF Conversion (EBITDA) | - | 36.48% | 139.02% | - | - | 9.83% | 46.9% |
FCF Conversion (Net income) | - | - | 287.93% | - | - | 20.72% | 89.57% |
Dividend per Share 2 | - | - | - | - | - | - | - |
Announcement Date | 4/29/21 | 3/30/22 | 3/30/23 | 3/28/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 S1 | 2021 Q3 | 2022 S1 | 2024 Q1 |
---|---|---|---|---|
Net sales 1 | 24.01 | 12.69 | - | 10.5 |
EBITDA 1 | - | 1.566 | - | -0.1 |
EBIT 1 | - | 1.227 | - | -0.5 |
Operating Margin | - | 9.67% | - | -4.76% |
Earnings before Tax (EBT) | - | - | 2.389 | - |
Net income | -2.197 | - | 2.351 | - |
Net margin | -9.15% | - | - | - |
EPS | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 8/11/21 | 11/18/21 | 8/11/22 | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - |
Net Cash position 1 | - | 29.8 | 36.3 | - | 11.3 | 12 | 18.3 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | 1.77 | 7.74 | - | -8.77 | 0.77 | 6.3 |
ROE (net income / shareholders' equity) | - | 7.95% | 6.54% | - | 3.33% | 10.9% | 18.2% |
ROA (Net income/ Total Assets) | - | - | 4.72% | - | 2% | 6.3% | 11.6% |
Assets 1 | - | - | 56.99 | - | 51.67 | 58.73 | 60.63 |
Book Value Per Share 2 | - | 4.790 | 4.990 | - | 3.700 | 4.100 | 4.900 |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | 1.66 | 3.28 | - | 4.17 | 5.7 | 4.9 |
Capex / Sales | - | 3.24% | 5.88% | - | 8.16% | 9.69% | 6.99% |
Announcement Date | 4/29/21 | 3/30/22 | 3/30/23 | 3/28/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- APPH Stock
- APPH Stock
- Financials Apontis Pharma AG